We are live on ! Find out more
DMAAR

Drugs Made In America Acquisition Corp Rights
DMAAR

32 hedge funds and large institutions have $3.07M invested in Drugs Made In America Acquisition Corp Rights in 2025 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 6 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 2

0% more funds holding

Funds holding: 32 → 32 (0)

33% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 6

57% less capital invested

Capital invested by funds: $7.1M → $3.07M (-$4.03M)

Holders
32
Holders Change
–
Holders Change %
0%
% of All Funds
0.39%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
4
Reduced
6
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BNP Paribas Financial Markets
BNP Paribas Financial Markets
France
+$23.2K
2
DAM
DLD Asset Management
New York
+$19.7K
3
RCM
Rivernorth Capital Management
Florida
+$19.4K
4
HCM
Highbridge Capital Management
New York
+$7.86K
5
SCM
Shaolin Capital Management
Florida
+$4.85K

Top Sellers

Rank Fund Capital Flow
1
AA
AQR Arbitrage
Connecticut
-$23.2K
2
Parallax Volatility Advisers
Parallax Volatility Advisers
California
-$19.1K
3
HCM
Heights Capital Management
California
-$10.7K
4
GCL
Glazer Capital LLC
New York
-$9.98K
5
CS
Clear Street
New York
-$6.53K
Name Holding Trade Value Shares
Change 		Change in
Stake
PAMP
1
Polar Asset Management Partners
Ontario, Canada
$356K – – –
Hudson Bay Capital Management
2
Hudson Bay Capital Management
Connecticut
$284K – – –
HCI
3
Harraden Circle Investments
New York
$281K – – –
Toronto Dominion Bank
4
Toronto Dominion Bank
Ontario, Canada
$188K +$582 +3,000 +0.3%
AC
5
Aristeia Capital
Connecticut
$165K – – –
HCM
6
Highbridge Capital Management
New York
$162K +$7.86K +40,512 +4%
MP
7
Mangrove Partners
Connecticut
$159K – – –
LA
8
Linden Advisors
New York
$148K – – –
CS
9
Clear Street
New York
$117K -$6.53K -33,658 -5%
SCM
10
Shaolin Capital Management
Florida
$112K +$4.85K +25,000 +4%
BFM
11
Boothbay Fund Management
New York
$107K – – –
WAM
12
Wolverine Asset Management
Illinois
$105K – -2 -0%
GCL
13
Glazer Capital LLC
New York
$101K -$9.98K -51,448 -9%
LP
14
LMR Partners
United Kingdom
$93.7K – – –
WCMNY
15
Westchester Capital Management (New York)
New York
$79K – – –
RCM
16
Rivernorth Capital Management
Florida
$78.3K +$19.4K +100,000 +31%
WA
17
Whitebox Advisors
Minnesota
$74.9K – – –
AGM
18
Alpine Global Management
New York
$67.9K – – –
AA
19
AQR Arbitrage
Connecticut
$60.1K -$23.2K -119,686 -24%
RCM
20
Radcliffe Capital Management
Pennsylvania
$56.5K – – –
CCM
21
Context Capital Management
California
$46.8K – – –
CL
22
CSS LLC
Illinois
$46.8K – – –
HCM
23
Heights Capital Management
California
$37K -$10.7K -55,193 -19%
BI
24
Bulldog Investors
New Jersey
$24.4K – – –
BNP Paribas Financial Markets
25
BNP Paribas Financial Markets
France
$22.4K +$23.2K +119,686 New
1
2

DMAAR Hedge Fund Activity: Q4 2025 in Review

32 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Drugs Made In America Acquisition Corp Rights (DMAAR) for Q4 2025, worth a combined $3.07M — down 57% from $7.1M a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new DMAAR positions and 2 closed out — a net gain of 1 holder — while 4 added to existing stakes and 6 trimmed.

The largest buyer was BNP Paribas Financial Markets, opening a new position worth an estimated $23.2K. The largest seller was AQR Arbitrage, cutting an estimated $23.2K.

  • 32 institutional investors held Drugs Made In America Acquisition Corp Rights (DMAAR) as of Q4 2025, unchanged from Q3 2025.
  • Funds reported $3.07M of Drugs Made In America Acquisition Corp Rights stock for Q4 2025, down 57% quarter-over-quarter.
  • 3 funds opened new Drugs Made In America Acquisition Corp Rights positions in Q4 2025 and 2 closed out, a net change of +1 holder.
  • The largest Drugs Made In America Acquisition Corp Rights buyer in Q4 2025 was BNP Paribas Financial Markets, an estimated $23.2K added.
  • The largest Drugs Made In America Acquisition Corp Rights seller in Q4 2025 was AQR Arbitrage, an estimated $23.2K sold.

Based on aggregated 13F filings for Q4 2025.